|
Description of Business (Details) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2014
Antibody
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|---|---|---|---|---|
| Description of Business [Abstract] | ||||
| Number of classes of preclinical antibodies | 3xoma_NumberOfClassesOfPreclinicalAntibodies | |||
| Accumulated deficit incurred | $ (1,119,477)us-gaap_RetainedEarningsAccumulatedDeficit | $ (1,081,176)us-gaap_RetainedEarningsAccumulatedDeficit | ||
| Cash and cash equivalents | $ 78,445us-gaap_CashAndCashEquivalentsAtCarryingValue | $ 101,659us-gaap_CashAndCashEquivalentsAtCarryingValue | $ 45,345us-gaap_CashAndCashEquivalentsAtCarryingValue | $ 48,344us-gaap_CashAndCashEquivalentsAtCarryingValue |
| X | ||||||||||
|
- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Number of classes of preclinical antibodies for the treatment of diabetes. No definition available.
|